Advertisement

Chemotherapie des Krebses

  • Frederick H. Meyers
  • Ernest Jawetz
  • A. Goldfien

Zusammenfassung

Mit Krebs bezeichnet man neoplastische Erkrankungen, die beim Menschen in allen Lebensaltern und in allen Rassen auftreten. Die Incidenz, die geographische Verteilung und das Verhalten einzelner Krebsarten hängt von vielen Faktoren ab, einschließlich Geschlecht, Alter, Rasse, genetischer Prädisposition und carcinogenen Umweltfaktoren. Neure Erkenntnisse zeigen, daß einzelne DNA-Viren der Herpes-Gruppe und RNA-Viren vom „Typ C“, die eine große Anzahl von Tiercarcinomen verursachen können, möglicherweise auch beim Menschen carcinogen wirken. Man fand, daß onkogene RNA-Viren eine umgekehrte (inverse) Transcriptase enthalten, mit der die onkogene Information der Virus-RNA in die Basensequenz der Wirt-DNA eingebaut werden kann. Auch wenn das Virusgenom essentiell für die Entstehung einzelner menschlicher Tumoren ist, beeinflussen wahrscheinlich zusätzliche Erb-und Umweltfaktoren die neoplastische Entartung einer ehemals latenten Virusinfektion.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Adamson, R.H.: Antitumor activity and other biological properties of L.-asparaginase: A review. Cancer Chemother. Rep. 52, 617, (1968).PubMedGoogle Scholar
  2. Adamson, R.H.: Antitumor activity and other biological properties of L.-asparaginase: A review. Cancer Chemother. Rep. 52, 626 (1968).Google Scholar
  3. Alexanian, R. and others: Treatment of multiple myeloma: Combination chemotherapy with different melphalan dose regimens. JAMA 208, 1685 (1969).CrossRefGoogle Scholar
  4. American Cancer Society: Hormones and chemotherapy for cancer. 18, 1517–1666 (1965).Google Scholar
  5. Baserga, R. (editor): The Cell Cycle and Cancer. Dekker 1971.Google Scholar
  6. Baxter, J.D. and others: Glucocorticoid receptors in lymphoma cells in culture: Relationship to glucocorticoid killing activity. Science 171, 189–191 (1971).PubMedCrossRefGoogle Scholar
  7. Bertino, J.R., Huennekens, F.M., (editors): Folate antagonists as chemotherapeutic agents. Ann. New York Acad. Sc. 186, 1–519 (1971).Google Scholar
  8. Bruce, W. R., Lin, H.: Cellular approach to cancer chemotherapy. Cancer Res. 29, 2308–2310 (1969).PubMedGoogle Scholar
  9. Burchenal, J. H., Ellison, R. R.: The pyrimidine and purine antagonists. Clin. Pharmacol. Therap. 2, 523–541 (1961).Google Scholar
  10. Carbone, P.P. (moderator): Lung cancer: Perspectives and prospects. Ann. Int. Med. 73, 1003–1024 (1970).Google Scholar
  11. Cline, M. J.: Cancer Chemotherapy. Saunders 1971.Google Scholar
  12. Cohen, S. S.: Introduction to the biochemistry of D-arabinosylnucleosides. Progr. Nucleic. Acid Res. Molec. Biol. 5, 1–88 (1966).CrossRefGoogle Scholar
  13. Corticosteroide im letzten Stadium des Karzinoms. Arzneimittelbrief 8, 72–73 (1974).Google Scholar
  14. De Vita, V.T., Jr. and others: Combination chemotherapy in the treatment of advanced Hodgkin’s disease. Ann. Int. Med. 73, 881–895 (1970).Google Scholar
  15. Dollinger, M. R. and others: Quinacrine in the treatment of neoplastic effusions. Ann. Int. Med. 66, 249–257 (1967).PubMedGoogle Scholar
  16. Fairley, K.F., Simister, J.M.: Cyclophosphamide. Williams & Wilkins 1965.Google Scholar
  17. Frei, E., III, Freireich, E. J.: Progress and perspectives in the chemotherapy of acute leukemia. Advances Chemother. 2, 269 (1965).Google Scholar
  18. Galton, D.A.G., and others: The use of chlorambucil (Leukeran) and steroids in the treatment of chronic lymphocytic leukemia. Brit. J. Haemat. 7, 73–98 (1961).PubMedCrossRefGoogle Scholar
  19. Gee, T., Yu, K.P., Clarkson, B.D.: Treatment of adult leukemia with arabinosylcytosine and thioguanine. Cancer 23, 1019–1032 (1969).PubMedCrossRefGoogle Scholar
  20. Hambsch, Klugmann: Klinische Onkologie. Jena 1971.Google Scholar
  21. Heidelberger, C.: Cancer chemotherapy with purine and pyrimidine analogs. Ann. Rev. Pharmacol. 7, 101–124 (1967).PubMedCrossRefGoogle Scholar
  22. Henderson, E.S.: Treatment of acute leukemia. Seminars Hemat. 6, 271–319 (1969).Google Scholar
  23. Hryniuk, W. and others: Treatment of leukemia with large doses of methotrexate and folinic acid: Clinical-biochemical correlates. J. Nat. Cancer Inst. 48, 2410–2155 (1969).Google Scholar
  24. Hutter, A.M., Kayhoe, D.F.: Adrenal cortical carcinoma: Results of treatment with o.p. DDD in 138 patients. Am. J. Med. 41, 572–592 (1966).PubMedCrossRefGoogle Scholar
  25. James, D. H., Jr., Beckwith, J. B., Swinn, J. L.: Vincristine in children with malignant solid tumors. J. Pediat. 64, 534–541 (1964).PubMedCrossRefGoogle Scholar
  26. Jell, A.M., Marks, J., (editors): Natulan-Ibenzmethyzin. (Bristol) J. Wright & Sons: 1965.Google Scholar
  27. Jones, B. and others: Daunomycin in the treatment of advanced childhood lymphoblastic leukemia. Cancer Res. 31, 84–90 (1971).PubMedGoogle Scholar
  28. Karnofsky, D. A. (editor): Comparative clinical and biological effects of alkylating agents. Ann. New York Acad. Sc. 66, 657–1266 (1958).Google Scholar
  29. Kaufman, R. J.: Management of advanced ovarian carcinoma. M. Clin. North America 50, 845–856 (1966).Google Scholar
  30. Kennedy, B. J.: Mithramycin therapy in advanced testicular neoplasms. Cancer 26, 755–766 (1970).PubMedCrossRefGoogle Scholar
  31. Krakoff, I. H. (editor): Symposium on medical aspect of cancer. M. Clin. North America 55, 525–787 (1971).Google Scholar
  32. Krakoff, I.H.: Chemotherapy and hormonal therapy of carcinoma of the breast. Pages 77–83 in: Cancer Chemotherapy. Brodsky, I., & others (editors). Grune & Stratton 1967.Google Scholar
  33. Krakoff, I.H., Meyer, R.: Prevention of hyperuricemia in leukemia and lymphoma: Use of allopurinol. JAMA 193, 1–6 (1965).PubMedGoogle Scholar
  34. Lawley, P., Brooks, P.: Interstrand crosslinking of DNA by difunctional alkylating agents. J. Molec. Biol. 25, 143–160 (1967).PubMedCrossRefGoogle Scholar
  35. Li, M. C., Hertz, R., Spencer, D.B.: Effect of methotrexate therapy upon choriocarcinoma. Proc. Soc. Ex-per. Biol. Med. 93, 361–366 (1956).Google Scholar
  36. Livingston, R.B., Carter, S.K.: Cytosine arabinoside: A clinical brochure. Part. I. Cancer Chemother. Rep. 53, 179–205 (1968).Google Scholar
  37. Livingston, R.B., Carter, S.K.: Single Agents in Cancer Chemotherapy. Plenum 1970.Google Scholar
  38. Livingston, R.B., Carter, S.K.: Daunomycin: A chemotherapy fact sheet of the National Cancer Institute. March 1970.Google Scholar
  39. Newton, B. A.: Chemotherapeutic compounds affecting DNA structure and function. Advances Pharmacol. Chemother. 8, 149–184 (1970).CrossRefGoogle Scholar
  40. Perry, S. (editor): Human Tumor Cell Kinetics Lecture Series. Nat. Cancer Inst. Monogr. 30 (1969).Google Scholar
  41. Reifenstein, E.: Hydroxyprogesterone caproate therapy in advanced endometrial cancer. Cancer 27, 485–502 (1971).PubMedCrossRefGoogle Scholar
  42. Rhomes, J. A. and others: Central nervous system therapy and combination chemotherapy of childhood lymphocytic leukemia. Blood 37, 272–281 (1971).Google Scholar
  43. Ryser, H.J.-P.: Chemical carcinogenesis. New England J. Med. 285, 721–734 (1971).CrossRefGoogle Scholar
  44. Salmon, S.E.: Malignant disorders. Chap 30, pp 891–902, in: Current Diagnosis & Treatment. Krupp, MA., & M.J. Chatton (editors). Los Altos: Lange 1972.Google Scholar
  45. Schmidt, L.H. others: Comparative pharmacology of alkylating agents. Parts I–III. Cancer Chemother. Rep (Suppl 2) 1, 1528 (1965).Google Scholar
  46. Shambron, E., Miller, S., Fairbanks, V.F.: Intrathecal administration of amethopterin (methotrexate) in leukemic encephalopathy of young adults. New England J. Med. 265, 169–171 (1961).CrossRefGoogle Scholar
  47. Shastri, S. and others: Clinical study with bleomycin. Cancer 28, 1142–1146(1971).PubMedCrossRefGoogle Scholar
  48. Skipper, H.E.: Biochemical, biological, pharmacologie, toxicologic, kinetic and clinical relationships, Cancer 21, 600–610 (1968).PubMedCrossRefGoogle Scholar
  49. Skipper, H. E. and others: Implications of biochemical, pharmacologic and toxicologic relationships in the design of optimal therapy. Cancer Chemother. Rep. 54, 431 (1970).PubMedGoogle Scholar
  50. Stolinsky, D.C. and others: Clinical experience with procarbazine in Hodgkin’s disease, reticulum cell sarcoma, and lymphosarcoma. Cancer 26, 984–990 (1970).PubMedCrossRefGoogle Scholar
  51. Symposium: The actinomycins and their importance in the treatment of tumors in animals and man. Ann. New York Acad. Sc. 89, 283–486 (1960).Google Scholar
  52. Symposium on vincristine. Cancer Chemother. Rep. 52, 455–535 (1968).Google Scholar
  53. Tait, J.F., Burstein, S.: In vivo studies of steroid dynamics in man. The Hormones 5, 441–557 (1964).Google Scholar
  54. Tilney, N.L., Economou, S.G.: Chemotherapy of gastrointestinal cancer. Geriatrics 20, 265–276 (1965).Google Scholar
  55. Van Duuren, B. L. (editor): Biological effects of alkylating agents. Ann. New York Acad. Sc. 163, 589–1029 (1969).Google Scholar
  56. Wheeler, G.P.: Studies related to the mechanisms of action of cytotoxic alkylating agents. Cancer Res. 22, 651, (1962).PubMedGoogle Scholar
  57. Wheeler, G.P.: Studies related to the mechanisms of action of cytotoxic alkylating agents. Cancer Res. 22, 688 (1962).Google Scholar
  58. Whitmore, W. F., Jr.: Hormone therapy in prostatic cancer. Am. J. Med. 21, 697–713 (1956).PubMedCrossRefGoogle Scholar
  59. Wilson, C.B., and others: 1,3-Bis [2-chloroethyl]-1-nitrosourea (NSC-409962) in the treatment of brain tumors. Part. I. Cancer Chemother. Rep. 54, 273–281 (1970).PubMedGoogle Scholar
  60. Young, R. C. and others: Treatment of advanced Hodgkin’s disease with (1,3 bis [2-chloroethyl]-l -nitrosourea) BCNU. New England J. Med. 285, 475–479 (1971).CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin - Heidelberg 1975

Authors and Affiliations

  • Frederick H. Meyers
  • Ernest Jawetz
    • 1
  • A. Goldfien
    • 2
  1. 1.Department of Microbiology, School of MedicineUniversity of CaliforniaSan FranciscoUSA
  2. 2.Departments of Medicine and Obstetrics & Gynaecology and Cardiovascular Research Institute, School of MedicineUniversity of CaliforniaSan FranciscoUSA

Personalised recommendations